Precision Medicine and PET-Computed Tomography in Pediatric Malignancies.

Authors :: Sanli Y
Yilmaz E
Subramaniam RM
Source :: PET clinics [PET Clin] 2017 Oct; Vol. 12 (4), pp. 423-435. Date of Electronic Publication: 2017 Jul 28.
Publication Year :: 2017
Abstract: Fluorine-18 fluorodeoxyglucose ( <superscript>18</superscript> F-FDG) PET-computed tomography (CT) plays a significant role in diagnosis, staging, therapy selection, and therapy assessment of multiple pediatric malignancies and facilitating precision medicine delivery in pediatric patients. In patients with Hodgkin lymphoma, interim fludeoxyglucose <superscript>18</superscript> F-FDG PET/CT is highly sensitive and specific for predicting survival and multiple trials with FDG PET/CT-based adaptive therapies are currently ongoing. It is superior to iodine-131 metaiodobenzylguanidine ( <superscript>131</superscript> I-MIBG) scintigraphy and bone scintigraphy for detecting metastases in neuroblastoma patients and sarcoma patients. It may predict histologic differentiation and neoadjuvant therapy assessment in Wilms tumor.<br /> (Copyright © 2017 Elsevier Inc. All rights reserved.)